Mabwell Starts Trials of mAb to Regulate Iron Homeostasis In Vivo
publication date: Mar 15, 2023
Shanghai Mabwell has started a Phase I trial of 9MW301, the company’s iron homeostasis regulating macromolecular drug. The candidate is a mAb with an innovative target that Maxwell developed at its San Diego Innovation and R&D Center. In China, the mAb is a Category 1 Therapeutic Biological Product. 9MW3011 has been approved to begin trials in China and the US for two rare disease indications: β-thalassemia and polycythemia vera. In January 2023, Mabwell out-licensed global rights (ex-China) for the drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. More details....
Stock Symbol: (SHA: 688062)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.